Proprananol

Propranolol is a real drug with real evidence for a few conditions, and real dangers for some people. It is not a wellness supplement.

The strongest evidence in this retrieval is for migraine prevention. A 2024 meta-analysis of 20 trials and 1,291 people found propranolol cut monthly migraine days by about 1.3 days versus placebo, with roughly 179 more people per 1,000 getting at least a 50% reduction in headache days [1]. That is a modest but genuine benefit. In vestibular migraine, a 2025 network meta-analysis found propranolol had the strongest effect on vertigo attacks, but that conclusion rests on indirect evidence from small trials, several with high risk of bias [3]. In children, a 2006 review found only thin, methodologically weak trial evidence for any migraine preventive, propranolol included [2].

The safety picture is where the honesty matters. Propranolol is a beta-blocker: it slows the heart and can narrow airways. A 35-year-old asthmatic woman died after accidentally taking propranolol instead of prednisone, from acute bronchospasm and cardiac arrest [6]. In a cirrhosis trial, 27.69% of propranolol patients had adverse events (hypotension, bradycardia, asthma) versus 9.23% on carvedilol [4]. In akathisia studies, 17% withdrew from propranolol because of low blood pressure and slow heart rate [5]. For akathisia itself, propranolol produced no full remission in 31 patients across two 48-hour studies [5].

This retrieval does not cover propranolol's cardiac uses, dosing, or long-term safety data, so I cannot speak to those from these records. What it does show: benefit is real but modest for migraine, and the drug carries a documented risk of dangerous airway and heart-rate effects, especially in asthmatics.

My call: worth trying for migraine prevention if you have no asthma or heart block, with a doctor monitoring your pulse and blood pressure; not worth it for akathisia based on this evidence. Confidence: moderate.